Page last updated: 2024-11-01

ofloxacin and Benign Neoplasms

ofloxacin has been researched along with Benign Neoplasms in 36 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Research Excerpts

ExcerptRelevanceReference
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."9.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia."9.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
"Outpatient oral antibiotic therapy with oral ofloxacin for patients with low risk neutropenia and fever is safe and similar in efficacy to hospitalization and treatment with broad-spectrum parenteral antibiotics."9.09Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. ( Colomer, R; Cortés-Funes, H; García-Carbonero, R; Gómez, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Ruiz, A; Trigo, JM, 1999)
"The authors analyzed 27 breakthrough bacteremias occurring during ofloxacin prophylaxis in afebrile neutropenia over 7 years in 9989 admissions and 979 bacteremic and fungemic episodes in a National Cancer Center in Bratislava, Slovak Republic."7.69Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome. ( Demitrovicova, A; Drgona, L; Helpianska, L; Ilavska, I; Koren, P; Krcmery, V; Kukuckova, E; Lacka, J; Oravcova, E; Pichna, P; Rusnakova, V; Spanik, S; Studena, M; Trupl, J, 1996)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."5.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."5.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"These results suggest that tandem cycles of concurrent 96-h infusions of dexrazoxane and high-dose doxorubicin can be administered with minimal cardiac toxicity, and have activity in patients with recurrent sarcomas."5.11Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. ( Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y, 2004)
"We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia."5.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
"Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization."5.11Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. ( Billingham, L; Bower, M; Cullen, M; Fernando, I; Gaunt, C; Gollins, S; Hastings, M; Huddart, R; Rea, D; Simmonds, P; Stanley, A; Steven, N; Stuart, N, 2005)
"Outpatient oral antibiotic therapy with oral ofloxacin for patients with low risk neutropenia and fever is safe and similar in efficacy to hospitalization and treatment with broad-spectrum parenteral antibiotics."5.09Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. ( Colomer, R; Cortés-Funes, H; García-Carbonero, R; Gómez, C; Hidalgo, M; Hornedo, J; Lumbreras, C; Perea, S; Ruiz, A; Trigo, JM, 1999)
" After an initial work-up for fever, patients were randomized to receive oral ofloxacin 400 mg immediately and twice daily thereafter in the hospital or as outpatients."5.08Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. ( Aziz, Z; Karim, M; Khan, MA; Khan, WA; Malik, IA, 1995)
" We conducted a prospective non-randomised trial to evaluate the efficacy of administration of oral ofloxacin by caregivers to paediatric cancer patients with fever and neutropenia."5.08Out-patient management of febrile neutropenia in indigent paediatric patients. ( Malik, IA, 1997)
"A multicenter prospective nonrandomized trial was conducted to evaluate the efficacy of self-administered oral ofloxacin in the treatment of cancer patients with fever and neutropenia."5.07Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. ( Aziz, Z; Karim, M; Khan, WA; Malik, IA, 1994)
"The authors analyzed 27 breakthrough bacteremias occurring during ofloxacin prophylaxis in afebrile neutropenia over 7 years in 9989 admissions and 979 bacteremic and fungemic episodes in a National Cancer Center in Bratislava, Slovak Republic."3.69Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome. ( Demitrovicova, A; Drgona, L; Helpianska, L; Ilavska, I; Koren, P; Krcmery, V; Kukuckova, E; Lacka, J; Oravcova, E; Pichna, P; Rusnakova, V; Spanik, S; Studena, M; Trupl, J, 1996)
"FE rate was greatest for testicular cancer (27."2.73Rational selection of patients for antibacterial prophylaxis after chemotherapy. ( Billingham, LJ; Cullen, MH; Gaunt, CH; Steven, NM, 2007)
"Both cancer centers differed in prophylactic antibiotic policies."2.69Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998)
" three times daily with dosage adjustment according to renal function and body weight (group 2)."2.67Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. ( Maiche, AG; Teerenhovi, L, 1991)
"Thus, up to date management of cancer patients, in addition to other supportive care modalities, should also incorporate diagnostic methods and therapy of infections."2.47[Treatment and prevention of infections in cancer patients with neutropenia]. ( Sinkó, J, 2011)
"Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin."2.43Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. ( Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M, 2006)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."1.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)
"Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin- and methicillin-resistant staphylococci and enterococci."1.30In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. ( Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H, 1997)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's14 (38.89)18.2507
2000's17 (47.22)29.6817
2010's4 (11.11)24.3611
2020's1 (2.78)2.80

Authors

AuthorsStudies
Diamandis, P1
Wildenhain, J1
Clarke, ID1
Sacher, AG1
Graham, J1
Bellows, DS1
Ling, EK1
Ward, RJ1
Jamieson, LG1
Tyers, M1
Dirks, PB1
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L3
Hitosugi, T1
Zhang, L3
Zhang, S3
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y6
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S2
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J2
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A2
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Swaroop, C1
Agarwala, S1
Pandey, RM1
Bakhshi, S1
Petrosillo, N1
Sinkó, J1
Azéma, J1
Guidetti, B1
Korolyov, A1
Kiss, R1
Roques, C1
Constant, P1
Daffé, M1
Malet-Martino, M1
Samonis, G1
Koutsounaki, E1
Karageorgopoulos, DE1
Mitsikostas, P1
Kalpadaki, C1
Bozionelou, V1
Bompolaki, I1
Sgouros, J1
Taktikou, V1
Falagas, ME1
Cornely, OA1
Wicke, T1
Seifert, H1
Bethe, U1
Schwonzen, M1
Reichert, D1
Ullmann, AJ1
Karthaus, M1
Breuer, K1
Salzberger, B1
Diehl, V1
Fätkenheuer, G1
Chow, WA1
Synold, TW1
Tetef, ML1
Longmate, J1
Frankel, P1
Lawrence, J1
Al-Khadimi, Z1
Leong, L1
Lim, D1
Margolin, K1
Morgan, RJ1
Raschko, J1
Shibata, S1
Somlo, G1
Twardowski, P1
Yen, Y1
Doroshow, JH1
Bucaneve, G2
Micozzi, A1
Menichetti, F1
Martino, P2
Dionisi, MS1
Martinelli, G1
Allione, B1
D'Antonio, D2
Buelli, M1
Nosari, AM1
Cilloni, D1
Zuffa, E1
Cantaffa, R1
Specchia, G1
Amadori, S1
Fabbiano, F1
Deliliers, GL1
Lauria, F1
Foà, R1
Del Favero, A1
Cullen, M3
Steven, N2
Billingham, L2
Gaunt, C1
Hastings, M1
Simmonds, P1
Stuart, N1
Rea, D1
Bower, M1
Fernando, I1
Huddart, R1
Gollins, S1
Stanley, A1
Baden, LR2
Freifeld, AG1
Sepkowitz, KA1
Eller, P1
Pechlaner, C1
Ito, JI1
Tegtmeier, BR1
O'Donnell, MR1
Pasqualotto, AC1
Rosa, DD1
Machado, AL1
Almyroudis, NG1
Segal, BH1
Castagna, L1
Santoro, A1
Leibovici, L1
Paul, M1
Gafter-Gvili, A1
Fraser, A1
Kern, WV1
Cullen, MH1
Billingham, LJ1
Gaunt, CH1
Steven, NM1
Maiche, AG2
Muhonen, T1
Malik, IA3
Khan, WA2
Aziz, Z2
Karim, M2
Khan, MA1
Dholakia, N1
Rolston, KV2
Ho, DH2
LeBlanc, B2
Bodey, GP1
Spanik, S3
Trupl, J4
Ilavska, I1
Helpianska, L1
Drgona, L1
Demitrovicova, A2
Kukuckova, E2
Studena, M2
Pichna, P2
Oravcova, E3
Rusnakova, V2
Koren, P3
Lacka, J3
Krcmery, V5
Streeter, H1
Dvorak, T1
Kunova, A3
Botek, R1
Sorkovska, D1
Grey, E2
Krchnakova, A2
Svec, J2
Krupova, I3
Grausova, S2
Stopkova, K1
Kralóvicová, K1
Kaiserova, E1
Foltinova, A1
Kovacicova, G1
Kiskova, M1
West, D1
Krupova, Y1
Novotny, J1
Sabo, A1
Mateicka, F1
Hidalgo, M1
Hornedo, J1
Lumbreras, C1
Trigo, JM1
Colomer, R1
Perea, S1
Gómez, C1
Ruiz, A1
García-Carbonero, R1
Cortés-Funes, H1
Siegrist, HH1
Nepa, MC1
Jacquet, A1
Di Bonaventura, G1
Catamo, G1
Ballone, E1
Piccolomini, R1
Teerenhovi, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]547 participants (Anticipated)Observational [Patient Registry]2016-12-31Recruiting
A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors[NCT00005590]Phase 30 participants Interventional1999-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for ofloxacin and Benign Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
[Treatment and prevention of infections in cancer patients with neutropenia].
    Magyar onkologia, 2011, Volume: 55, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Bacterial In

2011
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
    Cancer, 2006, Oct-15, Volume: 107, Issue:8

    Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciproflox

2006

Trials

14 trials available for ofloxacin and Benign Neoplasms

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Administration, Oral; Adolescent; Ambulatory Care; Amikacin; Amoxicillin-Potassium Clavulanate Combi

2009
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibili

2004
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3

    Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule

2004
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacte

2005
Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineopl

2005
Rational selection of patients for antibacterial prophylaxis after chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; D

2007
Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Female; Granulocyte

1993
Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 19, Issue:3

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neoplasms; Ne

1994
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.
    The American journal of medicine, 1995, Volume: 98, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Feasibility Studies; Female; Fever; Fever of Unknown Origin; Humans; M

1995
Out-patient management of febrile neutropenia in indigent paediatric patients.
    Annals of the Academy of Medicine, Singapore, 1997, Volume: 26, Issue:6

    Topics: Administration, Oral; Adolescent; Ambulatory Care; Anti-Infective Agents; Child; Child, Preschool; F

1997
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:3

    Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A

1998
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Cancer, 1999, Jan-01, Volume: 85, Issue:1

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Amikacin; Anti-Bacterial Agents; Anti-Infective

1999
Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations.
    Infection, 1991, Volume: 19 Suppl 6

    Topics: Administration, Oral; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Gram-Negative Bacterial

1991

Other Studies

19 other studies available for ofloxacin and Benign Neoplasms

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic

2007
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
    Le infezioni in medicina, 2009, Volume: 17 Suppl 5

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infect

2009
Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacte
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:12

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Cell Line, Tumor; Cipr

2011
Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:7

    Topics: Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever of Unkn

2012
Prophylactic antimicrobial agents and the importance of fitness.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Drug Res

2005
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia;

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Neoplasms; Neutropenia;

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacterial; Hum

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Drug Resistance, Mult

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Bacteri

2006
Antibacterial prophylaxis in patients with cancer and neutropenia.
    The New England journal of medicine, 2006, Jan-05, Volume: 354, Issue:1

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Fever; Hospitalization; Humans;

2006
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:4

    Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Gram-Negative Bacteria; Gram-P

1994
Bacteremia and fungemia occurring during antimicrobial prophylaxis with ofloxacin in cancer patients: risk factors, etiology and outcome.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:5

    Topics: Bacteremia; Disease Outbreaks; Fungemia; Humans; Incidence; Microbial Sensitivity Tests; Neoplasms;

1996
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 39 Suppl B

    Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter

1997
Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis.
    Scandinavian journal of infectious diseases, 1997, Volume: 29, Issue:3

    Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Dru

1997
Resistance pattern of 2816 isolates isolated from 17631 blood cultures and etiology of bacteremia and fungemia in a single cancer institution.
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:6

    Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteremia; Cephal

1997
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
    International journal of antimicrobial agents, 1998, Volume: 10, Issue:4

    Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu

1998
Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study.
    The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl C

    Topics: Anti-Infective Agents; Bacteria; Hematologic Diseases; Hospital Units; Humans; Intensive Care Units;

1999
Comparison of Etest, agar dilution, broth microdilution and disk diffusion methods for testing in vitro activity of levofloxacin against Staphylococcus spp. isolated from neutropenic cancer patients.
    International journal of antimicrobial agents, 2002, Volume: 19, Issue:2

    Topics: Agar; Anti-Infective Agents; Culture Media; Diffusion; Drug Resistance, Microbial; Humans; Levofloxa

2002